NASDAQ:UTHR - United Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$117.49 +1.93 (+1.67 %)
(As of 06/20/2018 01:32 AM ET)
Previous Close$117.49
Today's Range$114.78 - $117.70
52-Week Range$100.57 - $152.55
Volume235,873 shs
Average Volume406,000 shs
Market Capitalization$5.11 billion
P/E Ratio10.79
Dividend YieldN/A
Beta1.32
United Therapeutics logoUnited Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy. In addition, the company develops implantable system for Remodulin; and the RemUnity system for delivery of intravenous and subcutaneous Remodulin; esuberaprost, RemoPro, and eNOS gene therapies for PAH; and organ transplantation-related technologies, including regenerative medicines, xenotransplantation, and ex-vivo lung perfusion. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.

Receive UTHR News and Ratings via Email

Sign-up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:UTHR
CUSIP91307C10
Phone301-608-9292

Debt

Debt-to-Equity Ratio0.11
Current Ratio5.13
Quick Ratio4.81

Price-To-Earnings

Trailing P/E Ratio10.79
Forward P/E Ratio9.01
P/E Growth30

Sales & Book Value

Annual Sales$1.73 billion
Price / Sales2.97
Cash Flow$12.0503 per share
Price / Cash9.75
Book Value$48.64 per share
Price / Book2.42

Profitability

EPS (Most Recent Fiscal Year)$10.89
Net Income$417.90 million
Net Margins27.74%
Return on Equity26.68%
Return on Assets19.25%

Miscellaneous

Employees800
Outstanding Shares43,540,000

United Therapeutics (NASDAQ:UTHR) Frequently Asked Questions

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

How will United Therapeutics' stock buyback program work?

United Therapeutics announced that its Board of Directors has initiated a share repurchase plan on Sunday, June 4th 2017, which permits the company to repurchase $250,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 4.6% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's leadership believes its shares are undervalued.

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) released its quarterly earnings data on Wednesday, May, 2nd. The biotechnology company reported $5.57 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $3.62 by $1.95. The biotechnology company earned $389.20 million during the quarter, compared to analysts' expectations of $393.96 million. United Therapeutics had a return on equity of 26.68% and a net margin of 27.74%. The business's revenue was up 5.0% on a year-over-year basis. During the same quarter last year, the business earned $3.61 earnings per share. View United Therapeutics' Earnings History.

When is United Therapeutics' next earnings date?

United Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for United Therapeutics.

What price target have analysts set for UTHR?

8 brokerages have issued 1-year price targets for United Therapeutics' stock. Their forecasts range from $95.00 to $232.00. On average, they anticipate United Therapeutics' stock price to reach $130.75 in the next year. View Analyst Ratings for United Therapeutics.

Who are some of United Therapeutics' key competitors?

Who are United Therapeutics' key executives?

United Therapeutics' management team includes the folowing people:
  • Dr. Martine A. Rothblatt, Founder, Chairman & CEO (Age 63)
  • Mr. Michael I. Benkowitz, Pres & COO (Age 46)
  • Mr. James C. Edgemond, CFO & Treasurer (Age 50)
  • Mr. Paul A. Mahon, Exec. VP, Gen. Counsel & Corp. Sec. (Age 54)
  • Kevin Gray, Sr. VP of Strategic Operations & Logistics

Has United Therapeutics been receiving favorable news coverage?

Media headlines about UTHR stock have trended somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. United Therapeutics earned a news sentiment score of 0.05 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 47.68 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (11.28%), Palo Alto Investors LP (3.73%), Old Mutual Global Investors UK Ltd. (2.21%), Dimensional Fund Advisors LP (2.20%), FIL Ltd (1.48%) and Thompson Siegel & Walmsley LLC (1.25%). Company insiders that own United Therapeutics stock include Christopher Causey, Christopher Patusky, Judy D Olian, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Institutional Ownership Trends for United Therapeutics.

Which institutional investors are selling United Therapeutics stock?

UTHR stock was sold by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Wells Fargo & Company MN, Royal Bank of Canada, Millennium Management LLC, BNP Paribas Arbitrage SA, Thompson Siegel & Walmsley LLC, Swiss National Bank and State of Tennessee Treasury Department. Company insiders that have sold United Therapeutics company stock in the last year include Christopher Causey, Judy D Olian, Martine A Rothblatt, Raymond Dwek and Richard Giltner. View Insider Buying and Selling for United Therapeutics.

Which institutional investors are buying United Therapeutics stock?

UTHR stock was purchased by a variety of institutional investors in the last quarter, including LSV Asset Management, BlackRock Inc., Mackay Shields LLC, Prudential Financial Inc., Robeco Institutional Asset Management B.V., UBS Group AG, Senzar Asset Management LLC and Ontario Teachers Pension Plan Board. View Insider Buying and Selling for United Therapeutics.

How do I buy shares of United Therapeutics?

Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is United Therapeutics' stock price today?

One share of UTHR stock can currently be purchased for approximately $117.49.

How big of a company is United Therapeutics?

United Therapeutics has a market capitalization of $5.11 billion and generates $1.73 billion in revenue each year. The biotechnology company earns $417.90 million in net income (profit) each year or $10.89 on an earnings per share basis. United Therapeutics employs 800 workers across the globe.

How can I contact United Therapeutics?

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at 301-608-9292 or via email at [email protected]


MarketBeat Community Rating for United Therapeutics (UTHR)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  343 (Vote Outperform)
Underperform Votes:  459 (Vote Underperform)
Total Votes:  802
MarketBeat's community ratings are surveys of what our community members think about United Therapeutics and other stocks. Vote "Outperform" if you believe UTHR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UTHR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.